Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IBS in 2022

Targeting the gut microenvironment in IBS to improve symptoms

Key studies published in 2022 further established the importance of alterations in the gut microenvironment and interactions with the enteric and central nervous systems in symptom generation in irritable bowel syndrome and suggested novel and clinically accessible therapeutic approaches for this large group of patients.

Key advances

  • Histamine, a known neuroimmune modulator, is produced by gut bacteria and can induce abdominal pain; therefore, bacterial histamine is an attractive therapeutic target for treating abdominal pain in irritable bowel syndrome (IBS)6.

  • Dietary advice using a FODMAP-lowering smartphone application was superior to a spasmolytic agent in primary care IBS, demonstrating its usefulness as a first-line treatment option for IBS in primary care9.

  • The intestinal adsorbent enterosgel (polymethylsiloxane polyhydrate), which is a readily available over-the-counter product, improved abdominal pain and diarrhoeal symptoms in patients with IBS with diarrhoea in a large double-blinded placebo-controlled 8-week clinical trial10.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: The gut microenvironment and neuroimmune interactions are important for symptom generation in IBS and other DGBI.

References

  1. Simrén, M. & Tack, J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat. Rev. Gastroenterol. Hepatol. 15, 589–605 (2018).

    Article  Google Scholar 

  2. Shanahan, F. & Quigley, E. M. M. Manipulation of the microbiota for treatment of IBS and IBD — challenges and controversies. Gastroenterology 146, 1554–1563 (2014).

    Article  Google Scholar 

  3. Mars, R. A. T. et al. Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome. Cell 183, 1137–1140 (2020).

    Article  CAS  Google Scholar 

  4. Mujagic, Z. et al. Integrated fecal microbiome–metabolome signatures reflect stress and serotonin metabolism in irritable bowel syndrome. Gut Microbes 14, 2063016 (2022).

    Article  Google Scholar 

  5. McIntosh, K. et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut 66, 1241–1251 (2017).

    Article  CAS  Google Scholar 

  6. De Palma, G. et al. Histamine production by the gut microbiota induces visceral hyperalgesia through histamine 4 receptor signaling in mice. Sci. Transl Med. 14, eabj1895 (2022).

    Article  Google Scholar 

  7. Barbara, G. et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 132, 26–37 (2007).

    Article  CAS  Google Scholar 

  8. Deiteren, A. et al. Histamine H4 and H1 receptors contribute to postinflammatory visceral hypersensitivity. Gut 63, 1873–1882 (2014).

    Article  CAS  Google Scholar 

  9. Carbone, F. et al. Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut 71, 2226–2232 (2022).

    Article  Google Scholar 

  10. Howell, C. A. et al. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D). Gut 71, 2430–2438 (2022).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Magnus Simrén.

Ethics declarations

Competing interests

M.S. declares research funding (paid to institution) from Glycom/DSM; advisory and/or consultancy for Danone Nutricia Research, Ironwood, Menarini, Biocodex, Genetic Analysis AS, DSM, Tillotts, Takeda, Arena, Kyowa Kirin, Adnovate, BioGaia and Pharmanovia; and speaker’s bureaus for Tillotts, Menarini, Kyowa Kirin, Takeda, Biocodex, AlfaSigma, Sanofi, Janssen Immunology, Pfizer, Ferrer, BioGaia and Falk Foundation.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Simrén, M. Targeting the gut microenvironment in IBS to improve symptoms. Nat Rev Gastroenterol Hepatol 20, 69–70 (2023). https://doi.org/10.1038/s41575-022-00718-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-022-00718-3

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing